Cover Image

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

Objective Activated astroglia is involved in the pathophysiology of neurodegenerative diseases and has also been described in animal models of spinal muscular atrophy (SMA). Given the urgent need of biomarkers for treatment monitoring of new RNA-modifying and gene replacement therapies in SMA, we ex...

Full description

Saved in:
Bibliographic Details
Main Authors: Freigang, Maren (Author) , Steinacker, Petra (Author) , Wurster, Claudia D. (Author) , Schreiber-Katz, Olivia (Author) , Osmanovic, Alma (Author) , Petri, Susanne (Author) , Koch, Jan Christoph (Author) , Rostásy, Kevin (Author) , Huss, André (Author) , Tumani, Hayrettin (Author) , Winter, Benedikt (Author) , Falkenburger, Björn (Author) , Ludolph, Albert C. (Author) , Otto, Markus (Author) , Hermann, Andreas (Author) , Günther, René (Author)
Format: Article (Journal)
Language:English
Published: 11 August 2022
In: Annals of Clinical and Translational Neurology
Year: 2022, Volume: 9, Issue: 9, Pages: 1437-1448
ISSN:2328-9503
DOI:10.1002/acn3.51645
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/acn3.51645
Verlag, lizenzpflichtig, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/acn3.51645
Get full text
Author Notes:Maren Freigang, Petra Steinacker, Claudia D. Wurster, Olivia Schreiber-Katz, Alma Osmanovic, Susanne Petri, Jan C. Koch, Kevin Rostásy, André Huss, Hayrettin Tumani, Benedikt Winter, Björn Falkenburger, Albert C. Ludolph, Markus Otto, Andreas Hermann and René Günther
Description
Summary:Objective Activated astroglia is involved in the pathophysiology of neurodegenerative diseases and has also been described in animal models of spinal muscular atrophy (SMA). Given the urgent need of biomarkers for treatment monitoring of new RNA-modifying and gene replacement therapies in SMA, we examined glial fibrillary acidic protein concentrations in cerebrospinal fluid (cGFAP) as a marker of astrogliosis in SMA. Methods 58 adult patients and 21 children with genetically confirmed 5q-associated SMA from four German motor neuron disease specialist care centers and 30 age- and sex-matched controls were prospectively included in this study. cGFAP was measured and correlated to motor performance and disease severity. Additionally, we compared cGFAP with neurofilament light chain concentrations in cerebrospinal fluid (cNfL). Results cGFAP concentrations did not differ from controls but showed higher levels in more severely affected patients after adjustment for patients' age. Normalized cNfL values were associated with disease severity. Within 14 months of nusinersen treatment, cGFAP concentrations did not change, while cNfL decreased significantly. Interpretation cGFAP is not an outstanding biomarker in SMA, but might support the hypothesis that glial activation is involved in SMA pathology. Unlike previously suggested, cNfL may be a promising biomarker also in adult patients with SMA, which should be subject to further investigations.
Item Description:Gesehen am 19.09.2023
Physical Description:Online Resource
ISSN:2328-9503
DOI:10.1002/acn3.51645

Similar Items